Edition:
United Kingdom

G1 Therapeutics Inc (GTHX.OQ)

GTHX.OQ on NASDAQ Stock Exchange Global Select Market

38.87USD
24 Apr 2018
Change (% chg)

-- (--)
Prev Close
$38.87
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
77,218
52-wk High
$41.90
52-wk Low
$12.04

Latest Key Developments (Source: Significant Developments)

G1 Therapeutics qtrly ‍loss per share $0.55
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - G1 Therapeutics Inc ::G1 therapeutics reports third quarter 2017 financial results and recent operational highlights.G1 therapeutics inc - qtrly ‍loss per share $0.55.G1 therapeutics inc - qtrly loss per share ‍$0.55​.Q3 earnings per share view $-0.55 -- Thomson Reuters I/B/E/S.G1 therapeutics inc- ‍cash, cash equivalents and short-term investments totaled $118.4 million as of sept 30, 2017, versus $47.3 million as of dec 31, 2016​.  Full Article

G1 Therapeutics Inc appoints Barclay (Buck) Phillips as CFO and SVP, corporate development​
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - G1 Therapeutics Inc ::G1 Therapeutics Inc - appoints barclay (buck) phillips as chief financial officer and senior vice president, corporate development​.G1 Therapeutics Inc - ‍G1 announced that chief business officer Greg Mossinghoff will depart company in January of 2018​.  Full Article

BRIEF-G1 Therapeutics Announces Initiation Of Phase 1B/2 Clinical Trial Of G1T38 In Combination With Tagrisso

* G1 THERAPEUTICS ANNOUNCES INITIATION OF PHASE 1B/2 CLINICAL TRIAL OF G1T38 IN COMBINATION WITH TAGRISSO FOR EGFR-MUTANT NON-SMALL CELL LUNG CANCER